Summary

A multinational, randomized, double-blind, placebo-controlled Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD) [FOCUS; NCT01422213] has demonstrated the drug's efficacy in improving cognitive function and lessening depression symptoms [APA 2014 (poster NR6-114)].